Cognivue to Participate in Major Clinical Study with Global Alzheimer’s Platform

First FDA-cleared computerized test of cognitive function will be evaluated in the Bio-Hermes study; seeks to improve identification and screening of patients for early intervention and Alzheimer’s Disease trials

ROCHESTER, N.Y., APRIL 21, 2021Cognivue, Inc. today announced that its computerized, FDA-cleared technologies and proprietary algorithms have been selected by the Global Alzheimer’s Platform (GAP) to participate in its pioneering Bio-Hermes clinical trial study. Also participating in the study are Eli Lilly & Company, AbbVie, Merck, the Alzheimer’s Drug Discovery Foundation and other respected biopharma, technology, and nonprofit entities.

Bio-Hermes is the first-ever platform study to investigate and compare blood-based biomarkers, digital markers, and legacy assessments in 1,000 subjects over the age of 60 screened for Preclinical Alzheimer’s Disease (AD), Prodromal AD, or Mild Dementia AD. Use of biomarkers could lead to earlier and more frequent detection of amyloid build-up, prompting those affected to seek early intervention, including participation in clinical trials for Alzheimer’s prevention or treatment.

“We are excited about the collaboration with the Global Alzheimer’s Project and the opportunity to be part of the groundbreaking Bio-Hermes clinical study. This is the first wide-scale application of Cognivue technology along with state-of-the-art frontline diagnostic tools, such as, blood-based biomarkers and brain image scanning. This could be a milestone development to create a gold standard for the future of Alzheimer Disease assessment and diagnostics,” said Tom O’Neill, president and CEO of Cognivue. “Our ability to objectively, quantitatively, and reliably identify cognitive status further assist with the accurate diagnosis for potential cognitive impairment, which can then be treated or managed.”

Cognviue’s technologies are designed to provide healthcare providers a useful tool for cognitive evaluation and diagnosis. The digital system is engineered to eliminate bias and variability throughout the test that establish cognitive baselines and provide a concurrent monitoring vehicle for the evaluation and treatment of cognitive issues over time.

“The Bio-Hermes clinical trial will evaluate the most promising digital and blood biomarker tests, and we’re pleased to have Cognivue as one of our digital assessments for cognitive function,” said John Dwyer, president of the Global Alzheimer’s Platform Foundation. “This self-administered test could allow medical practices in any community to detect cognitive decline and prompt steps to diagnose Alzheimer’s. In turn, that means patients will be able to make timely decisions about treatment or participation in research.”

About Cognivue, Inc.

Cognivue, Inc. is a world-class neuroscience company focusing on cognitive health with the world’s first FDA-cleared computerized test of cognitive function.  The Cognivue device and technology are based on years of research that uses adaptive psychophysics to focus on cortical information processing by testing key cognitive domains. The technology significantly improves the ability of healthcare providers to implement a personalized assessment of cognitive function in a wide variety of care settings. The company is elevating the gold standard of cognitive health assessment and empowering the healthcare community to monitor, identify and act on early detection of cognitive health concerns. For more information, call 585-203-1969 or visit

 About the Global Alzheimer’s Platform

The Global Alzheimer’s Platform Foundation (GAP) is a patient-centric nonprofit dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Research centers across the US and Canada are part of the growing GAP Network (GAP-Net). GAP supports GAP-Net research centers by assisting with study start up and recruitment activities, promoting diversity in research studies, and offering national programs that champion brain health and the citizen scientists who make research possible.


Media Contacts

For Cognivue, Inc.

McDougall Communications

Christopher Knospe,, +1 (585) 434-2154

Mike McDougall, APR, Fellow PRSA,, +1 (585) 434-2150

 For Global Alzheimer’s Platform Foundation

Pamela Larkin,, +1 (408) 466-5952

Cognivue Bio-Hermes Clinical Trial Press Release